TPO and neoplasm: Interestingly, in this model, we still observed the striking potency of intravenous SAProsome-3, yielding durable tumor regression and complete responses in 50 and 66.7% of mice at 35 and 40 mg/kg of MSA-2–equivalent doses, respectively (Fig. 6a, b).